Mineralys Therapeutics is a publicly traded, clinical-stage biotechnology company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that we are developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
Mineralys is a fully remote company.
For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.
Ja – Mineralys Therapeutics hat aktuell 162 offene Stellen auf JobsRadar. 2 davon wurden in den letzten 30 Tagen ausgeschrieben. Davon machen 88 Angaben zum Gehalt – im Median $147,500 pro Jahr. 42 kamen in den letzten 24 Stunden dazu; zuletzt aktualisiert am 15. September 2026 um 15:52 UTC.